Can insulin signaling pathways be targeted to transport Aβ out of the brain?

Although the causal role of Amyloid-β (Aβ) in Alzheimer’s disease (AD) is unclear, it is still reasonable to expect that lowering concentrations of Aβ in the brain may decrease the risk of developing the neurocognitive symptoms of the disease. Brain capillary endothelial cells forming the blood-brain barrier (BBB) express transporters regulating the efflux of Aβ out of the cerebral tissue. Age-related BBB dysfunctions, that have been identified in AD patients, might impair Aβ clearance from the brain. Thus, targeting BBB outward transport systems has been suggested as a way to stimulate the clearance of Aβ from the brain. Recent data indicate that the increase in soluble brain Aβ and behavioral impairments in 3×Tg-AD mice generated by months of intake of a high-fat diet can be acutely reversed by the administration of a single dose of insulin. A concomitant increase in plasma Aβ suggests that clearance from the brain through the BBB is a likely mechanism for this rapid effect of insulin. Here, we review how BBB insulin response pathways could be stimulated to decrease brain Aβ concentrations and improve cognitive performance, at least on the short term.

[1]  F. Bilotta,et al.  Insulin and the Brain , 2017, Journal of intensive care medicine.

[2]  Yixue Xue,et al.  Effects of insulin combined with idebenone on blood–brain barrier permeability in diabetic rats , 2015, Journal of neuroscience research.

[3]  Arthur W. Toga,et al.  Blood-Brain Barrier Breakdown in the Aging Human Hippocampus , 2015, Neuron.

[4]  M. Roden,et al.  Effects of Intranasal Insulin on Hepatic Fat Accumulation and Energy Metabolism in Humans , 2015, Diabetes.

[5]  B. Strooper,et al.  Learning by failing: ideas and concepts to tackle γ-secretases in Alzheimer's disease and beyond. , 2015 .

[6]  A. Convit,et al.  Cerebral Perfusion in Insulin Resistance and Type 2 Diabetes , 2015, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[7]  F. Calon,et al.  Human Apolipoprotein E ε4 Expression Impairs Cerebral Vascularization and Blood—Brain Barrier Function in Mice , 2015, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[8]  Xiao-dong Liu,et al.  Alterations in function and expression of ABC transporters at blood-brain barrier under diabetes and the clinical significances , 2014, Front. Pharmacol..

[9]  Maiken Nedergaard,et al.  Impairment of paravascular clearance pathways in the aging brain , 2014, Annals of neurology.

[10]  R. Bateman,et al.  Amyloid‐β efflux from the central nervous system into the plasma , 2014, Annals of neurology.

[11]  B. Strooper,et al.  Lessons from a Failed γ-Secretase Alzheimer Trial , 2014, Cell.

[12]  G. Lewis,et al.  Intranasal Insulin Suppresses Endogenous Glucose Production in Humans Compared With Placebo in the Presence of Similar Venous Insulin Concentrations , 2014, Diabetes.

[13]  M. Garcia-Alloza,et al.  Prediabetes-induced vascular alterations exacerbate central pathology in APPswe/PS1dE9 mice , 2014, Psychoneuroendocrinology.

[14]  K. Blennow,et al.  Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography. , 2014, JAMA neurology.

[15]  B. Vissel,et al.  Inconsistencies and Controversies Surrounding the Amyloid Hypothesis of Alzheimer's Disease , 2014, Acta neuropathologica communications.

[16]  M. Morris,et al.  Dietary fat composition and dementia risk , 2014, Neurobiology of Aging.

[17]  M. Ihara,et al.  New Therapeutic Approaches for Alzheimer’s Disease and Cerebral Amyloid Angiopathy , 2014, Front. Aging Neurosci..

[18]  H. Hou,et al.  Methylene Blue Modulates β-Secretase, Reverses Cerebral Amyloidosis, and Improves Cognition in Transgenic Mice* , 2014, The Journal of Biological Chemistry.

[19]  E. Mormino The Relevance of Beta-Amyloid on Markers of Alzheimer’s Disease in Clinically Normal Individuals and Factors That Influence These Associations , 2014, Neuropsychology Review.

[20]  R. Hammer,et al.  Vascular and parenchymal amyloid pathology in an Alzheimer disease knock-in mouse model: interplay with cerebral blood flow , 2014, Molecular Neurodegeneration.

[21]  Michèle Desjardins,et al.  Aging-related differences in cerebral capillary blood flow in anesthetized rats , 2014, Neurobiology of Aging.

[22]  P. Scheltens,et al.  Cerebrospinal fluid levels of Alzheimer’s disease biomarkers in middle-aged patients with type 1 diabetes , 2014, Diabetologia.

[23]  A. Marette,et al.  INSULIN REVERSES THE HIGH FAT DIET-INDUCED INCREASE IN BRAIN Aβ AND IMPROVES MEMORY IN AN ANIMAL MODEL OF ALZHEIMER'S DISEASE , 2014, Alzheimer's & Dementia.

[24]  C. Kahn,et al.  Insulin Action in Brain Regulates Systemic Metabolism and Brain Function , 2014, Diabetes.

[25]  S. Ferreira,et al.  Inflammation, Defective Insulin Signaling, and Mitochondrial Dysfunction as Common Molecular Denominators Connecting Type 2 Diabetes to Alzheimer Disease , 2014, Diabetes.

[26]  Christian-Alexandre Castellano,et al.  Glucose hypometabolism is highly localized, but lower cortical thickness and brain atrophy are widespread in cognitively normal older adults. , 2014, American journal of physiology. Endocrinology and metabolism.

[27]  F. Calon,et al.  Altered cerebral vascular volumes and solute transport at the blood–brain barriers of two transgenic mouse models of Alzheimer's disease , 2014, Neuropharmacology.

[28]  F. Calon,et al.  Reduction in DHA transport to the brain of mice expressing human APOE4 compared to APOE2 , 2014, Journal of neurochemistry.

[29]  René Westerhausen,et al.  Intranasal insulin increases regional cerebral blood flow in the insular cortex in men independently of cortisol manipulation , 2014, Human brain mapping.

[30]  M. Sabbagh,et al.  Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease , 2014, Neurology.

[31]  Steven H. Liang,et al.  Alternative approaches for PET radiotracer development in Alzheimer's disease: imaging beyond plaque. , 2014, Journal of labelled compounds & radiopharmaceuticals.

[32]  C. Wellington,et al.  High-density lipoproteins and cerebrovascular integrity in Alzheimer's disease. , 2014, Cell metabolism.

[33]  E. Giralt,et al.  Reelin delays amyloid-beta fibril formation and rescues cognitive deficits in a model of Alzheimer’s disease , 2014, Nature Communications.

[34]  M. O. Olde Rikkert,et al.  Assessment of dynamic cerebral autoregulation and cerebrovascular CO2 reactivity in ageing by measurements of cerebral blood flow and cortical oxygenation , 2014, Experimental physiology.

[35]  M. Schubert,et al.  The role of neuronal insulin/insulin-like growth factor-1 signaling for the pathogenesis of Alzheimer's disease: possible therapeutic implications. , 2014, CNS & neurological disorders drug targets.

[36]  Kelly A. Tennant,et al.  Diabetes Augments In Vivo Microvascular Blood Flow Dynamics after Stroke , 2013, The Journal of Neuroscience.

[37]  Jean-Philippe Michaud,et al.  Real-time in vivo imaging reveals the ability of monocytes to clear vascular amyloid beta. , 2013, Cell reports.

[38]  C. Pike,et al.  Sex-Specific Effects of High Fat Diet on Indices of Metabolic Syndrome in 3xTg-AD Mice: Implications for Alzheimer's Disease , 2013, PloS one.

[39]  Daniel J. R. Christensen,et al.  Sleep Drives Metabolite Clearance from the Adult Brain , 2013, Science.

[40]  P. Barberger‐Gateau,et al.  Ageing and apoE change DHA homeostasis: relevance to age-related cognitive decline , 2013, Proceedings of the Nutrition Society.

[41]  S. Shimohama,et al.  Continuation of Exercise Is Necessary to Inhibit High Fat Diet-Induced β-Amyloid Deposition and Memory Deficit in Amyloid Precursor Protein Transgenic Mice , 2013, PloS one.

[42]  William A Banks,et al.  Blood–Brain Barrier Dysfunction as a Cause and Consequence of Alzheimer's Disease , 2013, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[43]  E. Siemers,et al.  A phase 3 trial of semagacestat for treatment of Alzheimer's disease. , 2013, The New England journal of medicine.

[44]  G. Landreth,et al.  Evidence for impaired amyloid β clearance in Alzheimer's disease , 2013, Alzheimer's Research & Therapy.

[45]  B. Courten,et al.  Advanced glycation end products (AGEs) are cross-sectionally associated with insulin secretion in healthy subjects , 2013, Amino Acids.

[46]  Johannes Kornhuber,et al.  The influence of insulin infusion on the metabolism of amyloid β peptides in plasma , 2013, Alzheimer's & Dementia.

[47]  J. Nicolazzo,et al.  Altered Brain Uptake of Therapeutics in a Triple Transgenic Mouse Model of Alzheimer’s Disease , 2013, Pharmaceutical Research.

[48]  Tammie L. S. Benzinger,et al.  Increased in Vivo Amyloid-β42 Production, Exchange, and Loss in Presenilin Mutation Carriers , 2013, Science Translational Medicine.

[49]  C. Hölscher,et al.  Intranasal Insulin as a Treatment for Alzheimer’s Disease: A Review of Basic Research and Clinical Evidence , 2013, CNS Drugs.

[50]  Francis Eustache,et al.  Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease , 2013, NeuroImage: Clinical.

[51]  K. Mullane,et al.  Alzheimer's therapeutics: continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond? , 2013, Biochemical pharmacology.

[52]  J. Ghersi-Egea,et al.  Physiology of blood-brain interfaces in relation to brain disposition of small compounds and macromolecules. , 2013, Molecular pharmaceutics.

[53]  M. Krams,et al.  2012: A watershed year for Alzheimer’s disease research , 2013, The journal of nutrition, health & aging.

[54]  K. Park,et al.  Altered APP Processing in Insulin-Resistant Conditions Is Mediated by Autophagosome Accumulation via the Inhibition of Mammalian Target of Rapamycin Pathway , 2012, Diabetes.

[55]  Y. Stern Cognitive reserve in ageing and Alzheimer's disease , 2012, The Lancet Neurology.

[56]  W. Banks,et al.  Insulin in the brain: there and back again. , 2012, Pharmacology & therapeutics.

[57]  B. Zlokovic,et al.  Neurovascular dysfunction and faulty amyloid β-peptide clearance in Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.

[58]  Huadong Zhou,et al.  Immunotherapy for Alzheimer disease—the challenge of adverse effects , 2012, Nature Reviews Neurology.

[59]  Ole A. Andreassen,et al.  A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline , 2012, Nature.

[60]  Berislav V. Zlokovic,et al.  Apolipoprotein E controls cerebrovascular integrity via cyclophilin A , 2012, Nature.

[61]  Y. Reijmer,et al.  Cerebral haemodynamics, cognition and brain volumes in patients with type 2 diabetes. , 2012, Journal of diabetes and its complications.

[62]  D. Holtzman,et al.  Measurement of apolipoprotein E and amyloid β clearance rates in the mouse brain using bolus stable isotope labeling , 2012, Molecular Neurodegeneration.

[63]  S. Watson,et al.  A Fully Human, Allosteric Monoclonal Antibody That Activates the Insulin Receptor and Improves Glycemic Control , 2012, Diabetes.

[64]  J. Schneider,et al.  Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. , 2012, The Journal of clinical investigation.

[65]  F. Tarazi,et al.  Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors. , 2012, Pharmacology & therapeutics.

[66]  I. Torres-Aleman,et al.  The many faces of insulin-like peptide signalling in the brain , 2012, Nature Reviews Neuroscience.

[67]  Hubert Preissl,et al.  Differential effects of intranasal insulin and caffeine on cerebral blood flow , 2012, Human brain mapping.

[68]  T. Montine,et al.  Intranasal Insulin Therapy for Alzheimer Disease and Amnestic Mild Cognitive Impairment A Pilot Clinical Trial , 2011 .

[69]  D. Alsop,et al.  Adhesion Molecules, Altered Vasoreactivity, and Brain Atrophy in Type 2 Diabetes , 2011, Diabetes Care.

[70]  B. Strooper,et al.  The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics , 2011, Nature Reviews Drug Discovery.

[71]  D. Bennett,et al.  Accumulation of Transactive Response DNA Binding Protein 43 in Mild Cognitive Impairment and Alzheimer Disease , 2011, Journal of neuropathology and experimental neurology.

[72]  B. Hyman,et al.  Neuropathological alterations in Alzheimer disease. , 2011, Cold Spring Harbor perspectives in medicine.

[73]  D. Selkoe,et al.  Resolving controversies on the path to Alzheimer's therapeutics , 2011, Nature Medicine.

[74]  H. Preissl,et al.  Insulin sensitivity of the human brain. , 2011, Diabetes research and clinical practice.

[75]  K. Niswender Basal Insulin: Physiology, Pharmacology, and Clinical Implications , 2011, Postgraduate medicine.

[76]  Saeid Taheri,et al.  Quantitative measurement of blood‐brain barrier permeability in human using dynamic contrast‐enhanced MRI with fast T1 mapping , 2011, Magnetic resonance in medicine.

[77]  D. H. Lee,et al.  Sink Hypothesis and Therapeutic Strategies for Attenuating Aβ Levels , 2011, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[78]  Todd E. Golde,et al.  Anti-Aβ Therapeutics in Alzheimer's Disease: The Need for a Paradigm Shift , 2011, Neuron.

[79]  W. Pardridge Drug transport in brain via the cerebrospinal fluid , 2011, Fluids and Barriers of the CNS.

[80]  A. Nordberg,et al.  Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer’s disease , 2010, Brain : a journal of neurology.

[81]  Toshiharu Suzuki,et al.  Increased amyloidogenic processing of transgenic human APP in X11-like deficient mouse brain , 2010, Molecular Neurodegeneration.

[82]  F. Calon,et al.  High-fat diet aggravates amyloid-beta and tau pathologies in the 3xTg-AD mouse model , 2010, Neurobiology of Aging.

[83]  C. Wellington,et al.  ATP-binding Cassette Transporter A1 Mediates the Beneficial Effects of the Liver X Receptor Agonist GW3965 on Object Recognition Memory and Amyloid Burden in Amyloid Precursor Protein/Presenilin 1 Mice* , 2010, The Journal of Biological Chemistry.

[84]  D. Holtzman,et al.  Overexpression of Low-Density Lipoprotein Receptor in the Brain Markedly Inhibits Amyloid Deposition and Increases Extracellular Aβ Clearance , 2009, Neuron.

[85]  F. Domoki,et al.  Cerebrovascular Responses to Insulin in Rats , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[86]  Keith A. Johnson,et al.  Cognition, Reserve, and Amyloid Deposition in Normal Aging , 2009, Annals of neurology.

[87]  M. Morris The role of nutrition in Alzheimer’s disease: epidemiological evidence , 2009, European journal of neurology.

[88]  Charles D. Smith,et al.  Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease , 2009, Neurobiology of Aging.

[89]  P. Talmud,et al.  Insulin stimulates hepatic low density lipoprotein receptor-related protein 1 (LRP1) to increase postprandial lipoprotein clearance. , 2009, Atherosclerosis.

[90]  Y. Xia,et al.  Downregulation of LPR1 at the blood–brain barrier in streptozotocin-induced diabetic mice , 2009, Neuropharmacology.

[91]  S. Cazaubon,et al.  The blood-brain barrier in brain homeostasis and neurological diseases. , 2009, Biochimica et biophysica acta.

[92]  I. Romero,et al.  P-Glycoprotein and Breast Cancer Resistance Protein Restrict Apical-to-Basolateral Permeability of Human Brain Endothelium to Amyloid-β , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[93]  F. LaFerla,et al.  Reduction of the cerebrovascular volume in a transgenic mouse model of Alzheimer's disease , 2009, Neuropharmacology.

[94]  Joanna M. Wardlaw,et al.  Blood–brain barrier: Ageing and microvascular disease – systematic review and meta-analysis , 2009, Neurobiology of Aging.

[95]  R. Deane,et al.  Clearance of amyloid-β peptide across the blood-brain barrier: Implication for therapies in Alzheimer’s disease , 2009 .

[96]  Katie Hamm,et al.  apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. , 2008, The Journal of clinical investigation.

[97]  M. Stoeckli,et al.  Dynamics of Aβ Turnover and Deposition in Different β-Amyloid Precursor Protein Transgenic Mouse Models Following γ-Secretase Inhibition , 2008, Journal of Pharmacology and Experimental Therapeutics.

[98]  Miles C. Miller,et al.  Hippocampal RAGE immunoreactivity in early and advanced Alzheimer's disease , 2008, Brain Research.

[99]  J. Born,et al.  Towards the therapeutic use of intranasal neuropeptide administration in metabolic and cognitive disorders , 2008, Regulatory Peptides.

[100]  H. Kroemer,et al.  MDR1‐P‐Glycoprotein (ABCB1) Mediates Transport of Alzheimer’s Amyloid‐β Peptides—Implications for the Mechanisms of Aβ Clearance at the Blood–Brain Barrier , 2007, Brain pathology.

[101]  D. Selkoe,et al.  Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide , 2007, Nature Reviews Molecular Cell Biology.

[102]  L. Mucke,et al.  100 Years and Counting: Prospects for Defeating Alzheimer's Disease , 2006, Science.

[103]  M. Goedert,et al.  A Century of Alzheimer's Disease , 2006, Science.

[104]  E. Golob,et al.  Vascular volume and blood‐brain barrier permeability measured by dynamic contrast enhanced MRI in hippocampus and cerebellum of patients with MCI and normal controls , 2006, Journal of magnetic resonance imaging : JMRI.

[105]  Miles C. Miller,et al.  RAGE, LRP-1, and amyloid-beta protein in Alzheimer’s disease , 2006, Acta Neuropathologica.

[106]  David M Holtzman,et al.  Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo , 2006, Nature Medicine.

[107]  W. Pan,et al.  Reciprocal interactions of insulin and insulin-like growth factor I in receptor-mediated transport across the blood-brain barrier. , 2006, Endocrinology.

[108]  M. Reger,et al.  Differential modulation of plasma β-amyloid by insulin in patients with Alzheimer disease , 2006, Neurology.

[109]  G. Schellenberg,et al.  Effects of intranasal insulin on cognition in memory-impaired older adults: Modulation by APOE genotype , 2006, Neurobiology of Aging.

[110]  V. Perry,et al.  Mechanisms to explain the reverse perivascular transport of solutes out of the brain. , 2006, Journal of theoretical biology.

[111]  L. Fratiglioni,et al.  Role of genes and environments for explaining Alzheimer disease. , 2006, Archives of general psychiatry.

[112]  A. Fagan,et al.  P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. , 2005, The Journal of clinical investigation.

[113]  D. Stern,et al.  Understanding RAGE, the receptor for advanced glycation end products , 2005, Journal of Molecular Medicine.

[114]  Jullie W Pan,et al.  Human Cerebral Blood Flow and Metabolism in Acute Insulin-Induced Hypoglycemia , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[115]  David W. Smith,et al.  Dynamics of β-Amyloid Reductions in Brain, Cerebrospinal Fluid, and Plasma of β-Amyloid Precursor Protein Transgenic Mice Treated with a γ-Secretase Inhibitor , 2005, Journal of Pharmacology and Experimental Therapeutics.

[116]  R. Deane,et al.  RAGE (Yin) Versus LRP (Yang) Balance Regulates Alzheimer Amyloid &bgr;-Peptide Clearance Through Transport Across the Blood–Brain Barrier , 2004, Stroke.

[117]  T. Terasaki,et al.  Brain Insulin Impairs Amyloid-β(1-40) Clearance from the Brain , 2004, The Journal of Neuroscience.

[118]  Hyoung-Gon Lee,et al.  Lessons from the AN 1792 Alzheimer vaccine: lest we forget , 2004, Neurobiology of Aging.

[119]  Patrick R Hof,et al.  Diet‐induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[120]  William A Banks,et al.  The source of cerebral insulin. , 2004, European journal of pharmacology.

[121]  Ronald C Petersen,et al.  Increased risk of type 2 diabetes in Alzheimer disease. , 2004, Diabetes.

[122]  G. Alexander,et al.  Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[123]  Keith A. Johnson,et al.  Neuropathology of Cognitively Normal Elderly , 2003, Journal of neuropathology and experimental neurology.

[124]  D. Holtzman,et al.  In Vivo Assessment of Brain Interstitial Fluid with Microdialysis Reveals Plaque-Associated Changes in Amyloid-β Metabolism and Half-Life , 2003, The Journal of Neuroscience.

[125]  Ann Marie Schmidt,et al.  RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain , 2003, Nature Medicine.

[126]  S. Asthana,et al.  Insulin increases CSF Aβ42 levels in normal older adults , 2003, Neurology.

[127]  S. D. Preston,et al.  Capillary and arterial cerebral amyloid angiopathy in Alzheimer's disease: defining the perivascular route for the elimination of amyloid β from the human brain , 2003, Neuropathology and applied neurobiology.

[128]  R. Malinow,et al.  APP Processing and Synaptic Function , 2003, Neuron.

[129]  Jan Born,et al.  Sniffing neuropeptides: a transnasal approach to the human brain , 2002, Nature Neuroscience.

[130]  D. Selkoe Clearing the Brain's Amyloid Cobwebs , 2001, Neuron.

[131]  A. Kastin,et al.  Glucose and Insulin Increase the Transport of Leptin through the Blood-Brain Barrier in Normal Mice but Not in Streptozotocin-Diabetic Mice , 2001, Neuroendocrinology.

[132]  A. Schmidt,et al.  The biology of the receptor for advanced glycation end products and its ligands. , 2000, Biochimica et biophysica acta.

[133]  R. Egleton,et al.  Insulin enhancement of opioid peptide transport across the blood-brain barrier and assessment of analgesic effect. , 2000, The Journal of pharmacology and experimental therapeutics.

[134]  P. S. St George-Hyslop Genetic Factors in the Genesis of Alzheimer's Disease , 2000, Annals of the New York Academy of Sciences.

[135]  M. Smith,et al.  Amyloid-β junkies , 2000, The Lancet.

[136]  O B Paulson,et al.  No effect of insulin on glucose blood-brain barrier transport and cerebral metabolism in humans. , 1999, Diabetes.

[137]  W. Banks,et al.  Uptake and degradation of blood-borne insulin by the olfactory bulb , 1999, Peptides.

[138]  K. Blennow,et al.  A population study on blood-brain barrier function in 85-year-olds , 1998, Neurology.

[139]  B. Greenberg,et al.  Turnover of Amyloid β-Protein in Mouse Brain and Acute Reduction of Its Level by Phorbol Ester , 1998, The Journal of Neuroscience.

[140]  W. Banks,et al.  Selective, Physiological Transport of Insulin Across the Blood-Brain Barrier: Novel Demonstration by Species-Specific Radioimmunoassays , 1997, Peptides.

[141]  W. Banks,et al.  Transport of Insulin Across the Blood-Brain Barrier: Saturability at Euglycemic Doses of Insulin , 1997, Peptides.

[142]  D. Dickson,et al.  Neuropathological Diagnosis of Alzheimer’s Disease: A Perspective from Longitudinal Clinicopathological Studies , 1997, Neurobiology of Aging.

[143]  Allan I. Levey,et al.  Familial Alzheimer's Disease–Linked Presenilin 1 Variants Elevate Aβ1–42/1–40 Ratio In Vitro and In Vivo , 1996, Neuron.

[144]  J. Hardy,et al.  Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1 , 1996, Nature.

[145]  G. Schellenberg,et al.  Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease , 1996, Nature Medicine.

[146]  W. Powers,et al.  Effect of stepped hypoglycemia on regional cerebral blood flow response to physiological brain activation. , 1996, The American journal of physiology.

[147]  J. Rommens,et al.  Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene , 1995, Nature.

[148]  D. Pollen,et al.  Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease , 1995, Nature.

[149]  Donald W. Miller,et al.  Identification and distribution of insulin receptors on cultured bovine brain microvessel endothelial cells: Possible function in insulin processing in the blood–brain barrier , 1994, Journal of cellular physiology.

[150]  C Cobelli,et al.  Saturable transport of insulin from plasma into the central nervous system of dogs in vivo. A mechanism for regulated insulin delivery to the brain. , 1993, The Journal of clinical investigation.

[151]  E. Ryding,et al.  The influence of hypoglycaemia on regional cerebral blood flow and cerebral volume in Type 1 (insulin-dependent) diabetes mellitus , 1993, Diabetologia.

[152]  C. Bucana,et al.  Differential permeability of the blood-brain barrier in experimental brain metastases produced by human neoplasms implanted into nude mice. , 1992, The American journal of pathology.

[153]  S. M. Sumi,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.

[154]  M. Pericak-Vance,et al.  Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease , 1991, Nature.

[155]  J. Nalbantoglu,et al.  Genetic Factors in Alzheimer's Disease , 1990, Journal of the American Geriatrics Society.

[156]  R. Moxley,et al.  Distribution of insulin receptor-like immunoreactivity in the rat forebrain , 1989, Neuroscience.

[157]  P. Halban,et al.  Intracellular pathways of insulin transport across vascular endothelial cells. , 1988, The American journal of physiology.

[158]  W. Pardridge,et al.  Blood-brain barrier transcytosis of insulin in developing rabbits , 1987, Brain Research.

[159]  W. Pardridge,et al.  Receptor-mediated peptide transport through the blood-brain barrier. , 1986, Endocrine reviews.

[160]  W. Pardridge,et al.  Enhanced Insulin Binding to Blood-Brain Barrier In Vivo and to Brain Microvessels In Vitro in Newborn Rabbits , 1985, Diabetes.

[161]  G. King,et al.  Receptor-mediated transport of insulin across endothelial cells. , 1985, Science.

[162]  M. Brownstein,et al.  Identification of insulin in rat brain. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[163]  H. Davson Blood–brain barrier , 1977, Nature.

[164]  M. Roth,et al.  The Association Between Quantitative Measures of Dementia and of Senile Change in the Cerebral Grey Matter of Elderly Subjects , 1968, British Journal of Psychiatry.

[165]  R. U. Margolis,et al.  Insulin in the Cerebrospinal Fluid , 1967, Nature.

[166]  F. Calon,et al.  The benefit of docosahexaenoic acid for the adult brain in aging and dementia. , 2015, Prostaglandins, leukotrienes, and essential fatty acids.

[167]  B. de Strooper,et al.  Learning by failing: ideas and concepts to tackle γ-secretases in Alzheimer's disease and beyond. , 2015, Annual review of pharmacology and toxicology.

[168]  Emily H. Trittschuh,et al.  Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia. , 2015, Journal of Alzheimer's disease : JAD.

[169]  Su Gao,et al.  Insulin inhibits Abeta production through modulation of APP processing in a cellular model of Alzheimer's disease. , 2014, Neuro endocrinology letters.

[170]  G. Pandini,et al.  Insulin has multiple antiamyloidogenic effects on human neuronal cells. , 2013, Endocrinology.

[171]  H. Fillit,et al.  Beyond amyloid: the future of therapeutics for Alzheimer's disease. , 2012, Advances in pharmacology.

[172]  F. Calon,et al.  ABCG2- and ABCG4-mediated efflux of amyloid-β peptide 1-40 at the mouse blood-brain barrier. , 2012, Journal of Alzheimer's disease : JAD.

[173]  W. Valentine,et al.  Long-acting insulin analogs: a review of "real-world" effectiveness in patients with type 2 diabetes. , 2011, Current diabetes reviews.

[174]  E. Cornford,et al.  Localization of brain endothelial luminal and abluminal transporters with immunogold electron microscopy , 2011, NeuroRX.

[175]  D. Selkoe Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[176]  R. Deane,et al.  Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease. , 2009, CNS & neurological disorders drug targets.

[177]  R. Carare,et al.  Lymphatic drainage of the brain and the pathophysiology of neurological disease , 2008, Acta Neuropathologica.

[178]  G. Schellenberg,et al.  Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. , 2008, Journal of Alzheimer's disease : JAD.

[179]  D. Bennett,et al.  Biochemical characterization of Abeta and tau pathologies in mild cognitive impairment and Alzheimer's disease. , 2007, Journal of Alzheimer's disease : JAD.

[180]  D. Bennett,et al.  Biochemical Characterization of Aβ and Tau Pathologies in Mild Cognitive Impairment and Alzheimer's Disease , 2007 .

[181]  J. Wands,et al.  Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes? , 2005, Journal of Alzheimer's disease : JAD.

[182]  J. Hendrick,et al.  Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor. , 2005, The Journal of pharmacology and experimental therapeutics.

[183]  J. Pickard,et al.  Symmetry of cerebral blood flow and cognitive responses to hypoglycaemia in humans , 2004, Diabetologia.

[184]  S. Asthana,et al.  Insulin increases CSF Abeta42 levels in normal older adults. , 2003, Neurology.

[185]  Weiming Xia,et al.  Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice , 1997, Nature Medicine.

[186]  H. Braak,et al.  Staging of Alzheimer-related cortical destruction. , 1997, International psychogeriatrics.

[187]  J. Hardy,et al.  Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. , 1996, Nature medicine.

[188]  G. Gessa,et al.  Possible role of insulin in the transport of tyrosine and tryptophan from blood to brain. , 1976, Advances in experimental medicine and biology.

[189]  Justin Paul,et al.  Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease , 2007, The Journal of experimental medicine.